Quantinno Capital Management LP Has $14.68 Million Holdings in Stryker Co. (NYSE:SYK)

Quantinno Capital Management LP grew its holdings in Stryker Co. (NYSE:SYK - Free Report) by 21.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 40,781 shares of the medical technology company's stock after buying an additional 7,075 shares during the quarter. Quantinno Capital Management LP's holdings in Stryker were worth $14,683,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. Elefante Mark B acquired a new position in Stryker during the 4th quarter worth $337,000. Chicago Capital LLC lifted its stake in shares of Stryker by 3.1% during the fourth quarter. Chicago Capital LLC now owns 195,052 shares of the medical technology company's stock valued at $70,228,000 after acquiring an additional 5,841 shares during the period. Zhang Financial LLC boosted its holdings in Stryker by 55.0% in the fourth quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company's stock valued at $41,366,000 after acquiring an additional 40,784 shares during the last quarter. Appleton Partners Inc. MA raised its holdings in Stryker by 5.0% during the 4th quarter. Appleton Partners Inc. MA now owns 29,222 shares of the medical technology company's stock worth $10,521,000 after purchasing an additional 1,400 shares during the last quarter. Finally, Metis Global Partners LLC boosted its stake in shares of Stryker by 10.2% in the 4th quarter. Metis Global Partners LLC now owns 16,841 shares of the medical technology company's stock valued at $6,064,000 after purchasing an additional 1,561 shares during the last quarter. 77.09% of the stock is owned by institutional investors.

Stryker Trading Down 0.0%

NYSE SYK opened at $387.92 on Wednesday. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $148.06 billion, a PE ratio of 49.99, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. The business's 50-day moving average price is $365.43 and its two-hundred day moving average price is $374.82.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, beating analysts' consensus estimates of $2.73 by $0.11. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The business had revenue of $5.87 billion during the quarter, compared to the consensus estimate of $5.68 billion. During the same quarter in the prior year, the firm posted $2.50 EPS. The company's revenue for the quarter was up 11.9% compared to the same quarter last year. On average, analysts expect that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be paid a $0.84 dividend. The ex-dividend date of this dividend is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.87%. Stryker's dividend payout ratio (DPR) is presently 45.41%.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the sale, the director now owns 3,417,326 shares in the company, valued at $1,288,195,208.96. This represents a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Allan C. Golston sold 2,458 shares of the firm's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the transaction, the director now owns 14,895 shares of the company's stock, valued at approximately $5,705,827.65. This represents a 14.16% decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.90% of the company's stock.

Analyst Ratings Changes

SYK has been the topic of a number of analyst reports. Roth Mkm increased their price target on Stryker from $405.00 to $456.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Truist Financial upped their target price on shares of Stryker from $390.00 to $400.00 and gave the stock a "hold" rating in a research note on Monday, May 5th. BTIG Research set a $403.00 price target on shares of Stryker and gave the stock a "buy" rating in a research note on Monday, April 14th. Stifel Nicolaus lifted their target price on Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a research report on Wednesday, January 29th. Finally, Canaccord Genuity Group increased their price target on shares of Stryker from $420.00 to $435.00 and gave the company a "buy" rating in a research note on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, Stryker currently has a consensus rating of "Moderate Buy" and an average target price of $427.05.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.